Article

Esophageal ulcer caused by cytomegalovirus: resolution during combination antiretroviral therapy for acquired immunodeficiency syndrome.

Department of Medicine, University of Alabama at Birmingham, 35294-0007, USA.
Southern Medical Journal (Impact Factor: 1.12). 09/2000; 93(8):818-20.
Source: PubMed

ABSTRACT A 36-year-old man with a 5-year history of untreated human immunodeficiency virus (HIV) infection had odynophagia for 14 days. Fifteen days earlier, he had begun taking trimethoprim-sulphamethoxazole and combination antiretroviral therapy that included lamivudine, zidovudine, and nelfinavir. He had no history of opportunistic infection. The CD4 lymphocyte count was 67/microL and HIV-RNA level was 359,396 copies/mL. Esophagogastroduodenoscopy revealed a large, well-circumscribed esophageal ulceration 31 cm from the incisors. Histopathologic examination of esophageal biopsy specimens showed cytopathic changes diagnostic of cytomegalovirus (CMV). In situ DNA hybridization was positive for CMV. While combination antiretroviral therapy was continued, the esophageal symptoms resolved within 4 days of endoscopy without specific therapy for CMV. Follow-up endoscopy 4 weeks later revealed a normal-appearing esophagus, and the patient has remained symptom-free for 10 months.

0 Bookmarks
 · 
17 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Opportunistic infections during primary infection with human immunodeficiency virus type 1 have occasionally been reported in the medical literature, and those caused by cytomegalovirus have tended to be severe and prolonged. We describe a 40-year-old man who had acute retroviral syndrome complicated by a severe cytomegalovirus-induced esophageal ulceration, which was successfully treated with total parenteral nutrition and ganciclovir in addition to highly active antiretroviral therapy.
    Clinical Infectious Diseases 02/2002; 34(1):E14-5. · 9.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Around one million people are affected by adenoviral keratoconjunctivitis a year in Japan, and it is recognized as one of the major pathogens of ophthalmological nosocomial infection worldwide. Although cidofovir can be used systemically for immunocompromised patients with disseminated adenoviral infection, no specific anti-adenoviral agent has been established for the treatment of adenoviral infection. We evaluated the anti-adenoviral effect of anti-HIV (human immunodeficiency virus) agents in this study. Five anti-HIV agents (zalcitabine, stavudine, nevirapine, indinavir and amprenavir) were subjected to in vitro evaluation. A549 cells were used for viral cell culture, and adenovirus serotypes 3, 4, 8, 19 and 37 were used. After calculating CC(50) (50% cytotoxic concentration) of each agent by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) method, we cultured adenovirus with the agents for seven days and quantitatively measured extracted adenoviral DNA by real-time PCR. Among the anti-HIV drugs, zalcitabine and stavudine, both nucleoside reverse transcriptase inhibitors, showed significant anti-adenoviral activity. In contrast, nevirapine, a non-nucleoside reverse transcriptase inhibitor, and indinavir and amprenavir, which are both protease inhibitors, were ineffective against adenovirus. These results indicate that zalcitabine and stavudine are possible candidates for the local and systemic treatment of adenoviral infection, and the anti-adenoviral effect might depend on the pharmacological properties of anti-HIV agents. The chemical properties on the clinical safety for systemic and local application need to be determined in order to for these drugs to be accepted for the treatment of adenovirus in clinical settings.
    Albrecht von Graæes Archiv für Ophthalmologie 10/2007; 245(9):1319-25. · 2.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gastrointestinal (GI) cytomegalovirus (CMV) disease occurs in adult patients with immune suppression. This study reviews and discusses the clinical settings, endoscopic features, and locations of GI CMV lesions. In total, 1950 endoscopic biopsy reports for all GI tract lesions in Chang Gung Memorial Hospital, Kaohsiung were retrospectively reviewed for CMV disease from 1999 to 2002. Only those patients found to be positive for viral inclusion bodies in tissue specimens, with further confirmation by special immunohistochemical staining, were enrolled in this study. Our series showed that all 5 patients were immunosuppressed when attacked by the virus. The esophagus (n = 2) and colon (n = 2) were infected in 4 patients, while stomach was involved in one patient. Those patients with lesions of the esophagus and stomach followed a more-benign clinical course. Endoscopic examination showed 1 or more prominent ulcers in the distal esophagus and at the antrum of the stomach. Rare endoscopic findings of diffuse esophageal CMV disease and severe and extensive colitis were presented. The overall mortality rate was 20%, and all but 1 patient responded well to ganciclovir treatment. We emphasize that GI CMV disease is still rare in Taiwan. A high degree of suspicion for CMV disease is important when diagnosing immunosuppressed patients suffering from GI symptoms.
    Chang Gung medical journal 08/2005; 28(7):467-75.